James H. Doroshow, MD has been director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute, since 2004. From 1983 to 2004, he served as chairman of the City of Hope Comprehensive Cancer Center’s Department of Medical Oncology and Therapeutics Research. From the time of his first research grant in 1980, Dr. Doroshow was continuously funded by NCI until he moved to the NIH in 2004. He is the author of more than 350 full-length publications in the areas of anthracycline antibiotic molecular pharmacology, the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to solid tumors. Dr. Doroshow served as a member of the Subspecialty Board on Medical Oncology of the American Board of Internal Medicine, chair of NCI’s Scientific Review Group A-Cancer Centers, and as a member of the FDA’s Oncologic Drugs Advisory Committee. He is currently a member of the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation.

Dr. Doroshow received his bachelor’s degree, magna cum laude, from Harvard College in 1969 and his medical degree from Harvard Medical School in 1973. After completing an internship and residency in Internal Medicine at the Massachusetts General Hospital in Boston, he spent three years performing his fellowship in Medical Oncology on the Medicine and Clinical Pharmacology Branches of the NCI.

He is co-author of Abeloff’s Clinical Oncology, 5th Edition.